



Pediatric Health Network

Children's National.

A few notes about today's Webinar

- All lines are muted throughout the webinar.
- Please use the Q&A box to ask questions or make comments.
- Today's Webinar recording and slides will be posted to the PHN website following the presentation. You can find past FOP presentations on our website at https://pediatrichealthnetwork.org/future-of-pediatrics/

Speakers



Elizabeth Estrada, MD

Conflicts to disclose:

• Consultant for Rhythm Pharmaceuticals

Upcoming FOP Talks!

DATE	TOPIC	SPEAKER
July 15	Abnormal Thyroid Labs in the Primary Care Setting	Priya Vaidyanathan, MD
	A Pediatrician's Approach to a Young Child With Joint Effusion	Bita Arabshahi, MD
July 29	Allergic Reactions: When to Refer?	Amaziah Coleman, MD Claire Boogaard, MD
	Dermatologic Manifestations of COVID-19	Anna Kirkorian, MD
August 12	Obstructive Sleep Apnea: Primary Care Management and When to Refer	Claire Lawlor, MD
	Neuropsychological Evaluations: What are they, when are they needed and how can I get them for my patients?	Kristina Hardy, PhD Laura Kenealy, PhD
August 26	Meeting Teens Where They Are: the Contraception Discussion	Brooke Bokor, MD, MPH Natasha Ramsey, MD
	School's Out: Supporting School Attendance and Distance Learning Engagement	Asad Bandealy, MD Heidi Schumacher, MD

PHN Webinars

July 7th — 12PM PCP Town Hall: Back to School Guidance featuring Nathaniel Beers, MD

https://childrensnational.org/healthcare-providers/refer-a-patient/covid/covid-19-webinars

July 8th – 12PM: PHN Office Manager and Practice Administrator Steering committee presents Practice Management: Road to Recovery Series

Link to register: https://cvent.me/mq8XxD or email PHN@childrensnational.org if you are interested in attending.

July 8	Reports and Recalls	
July 22	Payment Collection	
August 5	Best Practices: New Initiatives and Implementing Change	
August 19	Managing a COVID-19 positive Employee and Wellness In Your Workplace	


Prediabetes and Type 2 Diabetes: Diagnosis and Management

Elizabeth Estrada, MD Endocrinology

Objectives

- Discuss the epidemiology of type 2 diabetes and prediabetes in childhood
- Review the pathophysiology
- Discuss the screening guidelines, evaluation, and treatment of type 2 diabetes and prediabetes in childhood
- Review referral guidelines to type 2 diabetes clinic

Percent Obesity in Children 2-19y 1971-2016



Source: Data for 1971-2014: Fryar, C. D., Carroll, M. D., & Ogden, C. L. (2016). Prevalence of overweight and obesity among children and adolescents aged 2-19 years: United States, 1963-1965 through 2013-2014. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Retrieved from https://www.cdc.gov/nchs/data/hestat/obesity_child_13_14/obesity_child_13_14.pdf. Data for 2015-2016: Hales, C. M., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2017). Prevalence of obesity among adults and youth: United States, 2015-2016 (NSCH Data Brief No. 288). Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Retrieved from https://www.cdc.gov/nchs/products/databriefs/db288.htm.

Obesity Comorbidities:

Direct correlation with Severity of Obesity

Type 2 diabetes

Pre-diabetes

PCOS

Metabolic syndrome

Hypertension

Hyperlipidemia

Non-alcoholic fatty liver disease

Sleep apnea

GERD

Asthma

Orthopedic complications:

- Joint pain
- •SCFE, Blount's disease


Gallstones


Depression, body image

Eating disorders

Cancer

Incidence of Type 2 Diabetes in Youth





More than 4-fold increase projected in the next decades

N Engl J Med 2017;376:1419-1429

Prevalence Prediabetes

Cross-sectional analysis NHANES 2005-2016


- About 1 of 5 adolescents have prediabetes
 - •Increase from 1.8% in 1988-1994
 - •Higher in males and non-Hispanic Blacks

Increased risk for diabetes and CVD

Andes et al. JAMA Pediatr. 2020;174(2):e194498.


Pathophysiology

Insulin Resistance + β-cell Failure



Diabetes Complications: Earlier than Adults

Prevalence of Complications at Age 21



Prediabetes

Adults:

- 5%-10% will progress to diabetes within a year
- Risk factor for CVD
- 50-60% increased 5-year mortality
- DPP and other studies show lifestyle modifications and weight loss prevent progression of prediabetes to diabetes
 - Similar studies have not been conducted in adolescents

Screening Guidelines: Risk-based BMI ≥85%

One or more additional risk factors

- Maternal diabetes during the child's gestation
- Family history of type 2 diabetes in first- or second-degree relative
- High risk race/ethnicity:
 Native American, African American, Latino,
 Asian American, Pacific Islander)

- Signs or conditions associated with insulin resistance
 - Acanthosis nigricans
 - HTN
 - Dyslipidemia
 - PCOS
 - SGA

Screening Labs: Interpretation

Test	Pre-Diabetes		
	Impaired fasting glucose (IFG)	Impaired glucose tolerance (IGT)	Diabetes
Fasting Glucose	100-126 mg/dl		≥126 mg/dl
2-hr OGTT		140-200 mg/dl	≥200 mg/dl
Random Glucose			>200 mg/dl plus symptoms
HbA1C	5.7-6.4%		≥6.5%


Type 2 Diabetes in Children: Presentation


- Asymptomatic
- Vaginitis, UTI
- Polyuria, polydipsia, weight loss
- DKA or HHS, more frequent in blacks
- Obesity/overweight
- Acanthosis nigricans



Treatment

Challenge for the pediatric endocrinologist





Metformin

- First line therapy
- GI side effects
- 50% treatment failure within
 1 year

Increase dose by 500 mg increments:

- 1000 mg po BID
- 2,000 mg xtended release QD or


Monitor yearly:

- CBC, ALT, AST, creatinine
- Stop metformin:
 - Macrocytic anemia
 - AST/ALT >2.5 x upper normal
 - Creatinine >1.0


GLP-1 Analogs (Victoza, Trulicity, Ozempic)

- Enhance glucose-dependent insulin secretion
- Slow gastric emptying
- Weight loss
- Side effects: nausea, vomiting, pancreatitis

Liraglutide in Children and Adolescents with Type 2 Diabetes




GLP-1 analog (Victoza, daily SC injection)



SGLT-2 Inhibitors

- SGLT2: sodium-glucose transporter kidney
 - Glucose reabsorption
- Induce glycosuria




Other Medications


- Sulfonylurea
- Dipeptidyl peptidase 4 (DPP-4) inhibitors
- Colesevelam (Welchol)
- Thiazolidinediones (TZDs)
- Alpha-glucosidase inhibitors


Bariatric Surgery – Metabolic Surgery

- <u>TODAY</u>: Lifestyle and oral medications
- <u>Teen-LABS</u>: Bariatric surgery





Changes in HbA₁c





Weight Change and Remission of Diabetes and Hypertension Gastric Bypass Surgery - 5-Year Outcomes





Prediabetes and Type 2 Diabetes Referrals

These categories are for scheduling purposes only, not diagnostic criteria

HbA1c 5.7-6%

- Lifestyle intervention
- If the fasting glucose is >100 mg/dL or post-prandial >140 mg/dL \rightarrow prediabetes clinic

HbA1c 6%-7.0%

- Lifestyle intervention
- Refer to prediabetes clinic

HbA1c > 7.0%

• Refer to type 2 diabetes clinic

Significantly elevated blood glucose or HbA1c

• Urgent referral, on-call physician at 202-476-5000

Conclusions

- Type 2 diabetes and prediabetes are increasing in children
 - Parallel to obesity
 - Non-Hispanic Blacks, Hispanics and Native Americans are most affected
- Risk-based screening indicated in overweight and obese youth
- Prediabetes increases risk for diabetes and CVD in adults
- Recommended treatment of prediabetes is lifestyle modification
- \blacksquare Rapid β -cells loss leads to high therapeutic failure in youth with type 2 diabetes
- Type 2 diabetes complications appear earlier than adults
- More research is needed to understand the role of bariatric surgery





Pediatric Health Network

Children's National.